Advancement in Research and Development Activities to Induce Growth Rate Of Regenerative Medicine Market

The regenerative medicine market is anticipated to ride high on the wave of exponential growth throughout the forecast period of 2017-2025 due to the rising need for use of regenerative medicines for treating various diseases and disorders. Regenerative medicines are used to replace or repair organs and tissues impacted by any aging process, disease, or injury. These medicines help in reviving the cell and tissue functionalities and are also used in curing numerous degenerative disorders such as cardiovascular, orthopedic, and dermatology applications.

The regenerative medicine market, on the basis of product, is segmented into tissue engineering, small molecule & biologic, cell therapy, and gene therapy. The use of regenerative medicines across various applications such as wound healing, ophthalmology, dermatology, oncology, cardiovascular, dermatology, and others is helping to accelerate the growth rate of the regenerative medicine market. The growing prevalence of infectious diseases such as COVID-19, trauma emergencies, and shortage of organs for transplantation is driving the regenerative medicine market toward growth.

Get Sample Copy of this Report @

Cell Therapy to Be A Growth Generator For Regenerative Medicine Market

The new coronavirus pandemic has created havoc in the lives of billions of people across the globe through infecting a large number of populations, leading to massive death numbers. Researchers and scientists are in the process of finding a cure for COVID-19 on war-footing.

Various methods are being analyzed by the research and development wings of various organizations. Cell therapy is one of them. When a person develops severe symptoms of COVID-19, the body generates an excessive inflammatory response known as a cytokine storm that, in some cases, leads to acute respiratory distress syndrome (ARDS). Cell therapy is proving to be a ray of hope for treating ARDS. Athersys, a U.S. based biotech company is in the process of developing a cell therapy known as Multistem that decreases adverse results of inflammation. Thus, such developments in cell therapy eventually benefit the growth rate of the regenerative medicine market.

The growing demand for organ transplantation is also gaining considerable momentum across the globe and is projected to bring a rise in the growth rate of the regenerative medicine market. Growing support from the governments of various countries can also aid in the growth of the regenerative medicine market greatly.

Increasing Mergers and Acquisition Activities to Cast a Positive Impact On Regenerative Medicine Market

Also, mergers, acquisitions, collaborations, joint ventures, investments, and partnerships are likely to influence the growth rate of the regenerative medicine market in a positive way. The investment of Hackensack meridian Health in EpiBone, a regenerative medicine company is a classic instance. Hackensack Meridian Health has invested in a clinical-stage regenerative medicine company for the fourth time. This factor highlights the growing importance of the regenerative medicine market in the healthcare sector.

Key players involved in the regenerative medicine market are Stryker Corporation, Japan Tissue Engineering Co. Ltd., Vericel Corporation, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, Medtronic PLC, Acelity L.P.Inc., and Nuvasive Inc.

Check Table of Contents of this Report @

North America May Bring Good Growth Opportunities for Regenerative Medicine Market

The regenerative medicine market is regionally spread across the Middle East and Africa, Europe, North America, Latin America, and Asia Pacific. North America is likely to contribute largely to the growth rate of the regenerative medicine market during the forecast period due to increased demand for regenerative medicines across the forecast period and the growing research and development activities on finding a COVID-19 treatment. Asia Pacific is also expecting to record a steady growth rate across the forecast period due to increased funding for research and development activities across the region.

Private Funding Driving R&D Activities for Regenerative Medicine

San Francisco, California, January 04, 2017: Regenerative medicine promises to transform the way we see a number of chronic diseases, particularly cancer, and a number of research and development activities are currently underway to harness the possibilities with tissue engineering and molecular biology. In addition to the flooding of investment, a number of governments across the world are offering support to spur the innovation. Healthcare organizations such as FDA are offering policies to facilitate the development of future of medicine and guidelines are being changed. Consequently, the demand in the global regenerative medicine market is flourishing, according to a recent business and commerce study by TMR Research. The report is directed towards enabling more informed business decisions for audiences such as healthcare providers and clinical experts, therapeutic companies, and contract manufacturers.

The study has projected that the demand in the global regenerative medicine market will increment at a notable CAGR during the forecast period of 2017 to 2025, gaining traction from a number of factors such as government and private funding as an aid to support the harnessing of regenerative medicine, increasing healthcare expenditure across the urban parts of the world, growing prevalence of chronic diseases as well as genetic disorders, escalation in geriatric population, and increase in corporate partnerships, which in turn is accelerating the commercialization of regenerative medicines. On the other hand, lack of standard regulatory guidelines and ethical concerns pertaining to the usage of embryonic stem cell for research and development are a couple of factors obstructing the market from flourishing. Nevertheless, the stockholders connected to the value chain of the global regenerative medicine market are expected to find new revenue avenues if they concentrate on growing demand for organ transplantation and upcoming product pipeline.

The Food and Drug Administration has issued two policies on regenerative practices. While the first relates to autologous usage of tissues of cells and is intended towards transplantation, implantation, transfer, or infusion of human tissues, the second is for the manufacturers and healthcare providers to ensure minimal manipulation and homologous use of human cells and tissues.

Based on product type, the regenerative medicine market can be segmented into acellular products and cell-based products, whereas on the basis of therapy, the market can be bifurcated into gene therapy, cell therapy, immunotherapy, and tissue engineering. Application-wise, the regenerative medicine market can be classified into the fields of cardiology, diabetes, dermatology, orthopedic and musculoskeletal disorders, central nervous system diseases, and others such as autoimmune and dental or oral. The oncology segment is currently providing for the maximum demand, which is a reflection of growing prevalence of cancer across the globe as well as rich product pipeline.

Geographically, this report on the global regenerative medicine market gauges the potential of demand coming from every important region and country, such as China and India in Asia Pacific, the U.S. and Canada in North America, France, Germany, and the U.K. in Europe, and the Middle East and Africa. For each of these regions and countries, the report provides figures on how the demand has evolved in the recent past and how it is anticipated to multiply in the near future.

Owing to the inflow of a large number of players, the competitive landscape of the global regenerative medicine market reflects a fragmented scenario, with the focus on research and development activities. Some of the key companies are Integra LifeSciences Corporation, Organogenesis Inc., MiMedx Group, Inc, AstraZeneca, Medtronic, Acelity (KCI Concepts), Osiris Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Vericel Corporation, Stryker Corporation, Merck & Co., Inc., Pfizer Inc., Baxter and Nuvasive, Inc., Cook Biotech Inc., and C.R. Bard.

Get Sample Copy of this Report